KLK2: IHC Expression in Cancer and Radioligand Target Profile
KLK2, kallikrein related peptidase 2, is a protein. In Human Protein Atlas immunohistochemistry, KLK2 staining is highest in prostate cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is KLK2 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze KLK2 freeIs KLK2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ❔ Cell-surface accessibility: Localization not annotated.
- ✅ Tumor expression: High IHC staining in prostate cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
KLK2 IHC staining by cancer type
Protein expression of KLK2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Prostate Cancer | 0.93 | High | 100% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, lymphoma, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, gastric cancer, testicular cancer, endometrial cancer, glioma, liver cancer.
Is KLK2 internalized?
Nuclens has not yet extracted internalization evidence for KLK2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
KLK2 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for KLK2 yet. Search ClinicalTrials.gov for KLK2 trials.
KLK2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See KLK2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
KLK2 gene essentiality (DepMap)
CRISPR knockout effect across 1238 cancer cell lines: 0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related prostate cancer radioligand targets
PSMA (FOLH1) · HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · FAP · B7-H3 (CD276) · STEAP2
See all radioligand therapy targets in prostate cancer.
See how KLK2 ranks against 15,000 targets for your indication.
Analyze KLK2 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.